Aug. 21 at 10:26 AM
$LXRX Great buying opportunities around low
$2.20. (A thousand shares costing about
$2,200 now will be worth
$3K @
$3,
$5K @
$5,
$10K @
$10 and more.) These type of buying opportunities will come again often in the next year or two but at helically higher SP as we march towards sustainable revenue streams:
1) Last
$10M milestone payment from Novo in Q4/26;
2) Milestone payment up to
$12M from Vistris on ex-US/EU regulatory filings in Q4/26 and 2027 (including UAE, Bahrain, Saudi Arabia, Australia, New Zealand, Canada, Latin America and Asia);
3) Commercial milestone (ex-US/EU annual net sales tier thresholds) up to
$185M from Vistris on Inpefa sales in 2027 and beyond;
4) Tiered (10%-19%) royalties on Inpefa sales outside US/EU from Viatris in 2027 and beyond;
5) Zynquista/T1D sales in 00's of
$M to
$B's from 2027 to 2033;
6) Inpefa/HCM sales in 00's of M$ to B$ from 2028 2033;
7) LX9851 milestoned and royalties in the B$'s from 2029 and beyond.
Then, still have Pilavapadin to add.
